{
    "symbol": "RARE",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-05 21:53:08",
    "content": " Before we shift to the Q&A portion of the call, I'll provide a quick reminder of the key upcoming milestones for the company for GTX-102 in Angelman syndrome will provide an interim update in mid-2022 on Cohorts 4 and 5 in the Canada and U.K. arm of the study as well as available safety and efficacy data from the patients treated in the U.S. We Continue to be confident this program looks for opportunities to accelerate development."
}